Switch theme
Sign up to access all valuation multiples
Jinyu Bio-Technology Co Ltd is engaged in the development and sales of veterinary biological products. Its products are used for pigs, poultry, pets, and ruminants.
1992
907
LTM Revenue n/a
LTM EBITDA n/a
$925M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jinyu Bio-Technology Co. has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Jinyu Bio-Technology Co. achieved revenue of $220M and an EBITDA of $69.6M.
Jinyu Bio-Technology Co. expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jinyu Bio-Technology Co. valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $220M | n/a | XXX | XXX | XXX |
| Gross Profit | $151M | $116M | XXX | XXX | XXX |
| Gross Margin | 69% | NaN% | XXX | XXX | XXX |
| EBITDA | $69.6M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 32% | NaN% | XXX | XXX | XXX |
| Net Profit | $52.7M | $29.0M | XXX | XXX | XXX |
| Net Margin | 24% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Jinyu Bio-Technology Co.'s stock price is CNY 7 (or $1).
Jinyu Bio-Technology Co. has current market cap of CNY 8.0B (or $1.1B), and EV of CNY 6.7B (or $925M).
See Jinyu Bio-Technology Co. trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $925M | $1.1B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Jinyu Bio-Technology Co. has market cap of $1.1B and EV of $925M.
Jinyu Bio-Technology Co.'s trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Jinyu Bio-Technology Co.'s 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Jinyu Bio-Technology Co. and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $925M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpJinyu Bio-Technology Co.'s NTM/LTM revenue growth is n/a
Jinyu Bio-Technology Co.'s revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Jinyu Bio-Technology Co.'s ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Jinyu Bio-Technology Co.'s 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Jinyu Bio-Technology Co. and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 16% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 39% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jinyu Bio-Technology Co. acquired XXX companies to date.
Last acquisition by Jinyu Bio-Technology Co. was XXXXXXXX, XXXXX XXXXX XXXXXX . Jinyu Bio-Technology Co. acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Jinyu Bio-Technology Co. founded? | Jinyu Bio-Technology Co. was founded in 1992. |
| Where is Jinyu Bio-Technology Co. headquartered? | Jinyu Bio-Technology Co. is headquartered in China. |
| How many employees does Jinyu Bio-Technology Co. have? | As of today, Jinyu Bio-Technology Co. has 907 employees. |
| Is Jinyu Bio-Technology Co. publicy listed? | Yes, Jinyu Bio-Technology Co. is a public company listed on SHG. |
| What is the stock symbol of Jinyu Bio-Technology Co.? | Jinyu Bio-Technology Co. trades under 600201 ticker. |
| When did Jinyu Bio-Technology Co. go public? | Jinyu Bio-Technology Co. went public in 1999. |
| Who are competitors of Jinyu Bio-Technology Co.? | Similar companies to Jinyu Bio-Technology Co. include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Jinyu Bio-Technology Co.? | Jinyu Bio-Technology Co.'s current market cap is $1.1B |
| Is Jinyu Bio-Technology Co. profitable? | Yes, Jinyu Bio-Technology Co. is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
